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Abstract
The sequencing of the human genome holds out the hope for personalized medicine, but it is clear that analysis of DNA or
RNA content alone is not sufficient to understand most disease processes. Proteomic strategies that allow unbiased
identification of proteins and their post-transcriptional and -translation modifications are an essential complement to
genomic strategies. However, the enormity of the proteome and limitations in proteomic methods make it difficult to
determine the targets that are particularly relevant to human disease. Methods are therefore needed that allow rational
identification of targets based on function and relevance to disease. Screening methodologies such as phage display, SELEX,
and small-molecule combinatorial chemistry have been widely used to discover specific ligands for cells or tissues of
interest, such as tumors. Those ligands can be used in turn as affinity probes to identify their cognate molecular targets
when they are not known in advance. Here we report an easy, robust and generally applicable approach in which phage
particles bearing cell- or tissue-specific peptides serve directly as the affinity probes for their molecular targets. For proof of
principle, the method successfully identified molecular binding partners, three of them novel, for 15 peptides specific for
pancreatic cancer.
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Introduction
While the sequencing of the human genome was a great
advance for many areas of biology, the many steps between DNA
and protein, each of which is involved in complex, incompletely
understood feedback loops, make the link between them often
non-linear. For example, almost all sufferers of Down syndrome
share the same genetic flaw (trisomy 21), but the degree of
impairment varies greatly between individuals [1]. A study
examining closely related species shows small differences in
DNA sequence can become amplified in protein amino acid
sequences, with even greater differences in protein expression
levels [2]. These suggest that a true understanding of a disease
state will be more accurate when both genomic and proteomic
data is taken into account.
Unfortunately, studying the total protein expression of a cell is a
difficult task. The human genome codes for approximately 38,000
proteins [3]. With multiple isoforms, multiple post translational
modifications, and a 6 order of magnitude differences in
expression levels, verifying the presence of the entire proteome,
much less quantifying protein expression levels is beyond the
ability of today’s science. Restricting the proteomic study to the
plasma membrane allows simplification of the method while
retaining important information. Membrane proteins allow the
cell to sense and manipulate its environment, and are indicative of
processes in the cell. Resistance to chemotherapeutics by efflux
requires transport proteins on the membrane [4,5], metastasis is
initiated by changes in the proteins that interact with the stroma
[5–7], while cells undergoing growth and invasion express other
markers [8]. The assumption is that any cellular behavior of
interest will be reflected in the cell surface proteins, which greatly
reduces the number of proteins to examine.
Standard proteomic methods of identifying relevant membrane
proteins, such as biotinylation and capture [9,10] can yield
hundreds of proteins, most of which do not vary significantly in
expression levels between the diseased tissue and healthy cells.
Identifying and quantifying all these proteins on both the disease
model and the negative cell line by mass spectroscopy is a very
expensive and difficult undertaking typically performed in industry
or highly specialized academic laboratories. Afterwards, the
tedious task of comparing expression levels between the two data
sets and discarding the vast majority of invariant and uninteresting
proteins remains.
An alternative approach is to use screening methodologies such
as phage display, aptamers, or carefully planned small molecule
screens to probe the cell surface to identify functionally relevant
proteins. Phage display in particular is the longest-standing
platform amongst the display technologies with tens of thousands
of publications. However, the screening method leads to
compounds that bind to the proteins of interest, not the identity
of the proteins themselves. Optimizing affinity chromatography,
the standard method for determining the proteins phage derived
peptides bind to [11–14], is time consuming, and must be done for
each peptide clone. For a typical screen yielding several dozen
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Computer based methods, such as BLAST, yield a large number
of non-statistically significant matches, with no guarantee that any
are the real binding partner.
In this paper, we describe a functional proteomics method based
on phage display screening and biochemical techniques. The
described method is a robust, easy to use, and generally applicable
approach in which phage particles bearing cell- or tissue-specific
peptides serve directly as the affinity probes for their molecular
targets. For proof of principle, we have used this method to
identify the binding partners (three of which are novel biomarkers)
of 15 peptides from a phage display screen that are specific for
pancreatic cancer [15].
Materials and Methods
Cell culture
L3.6pl cells, a gift from professor Todd Bauer, were cultured in
MEM with 10% fetal bovine serum, 1% l-glutamine, and 1%
penicillin/streptomycin solution using established protocols.
Phage Labeling
Phage were grown to a concentration of at least 10
10 pfu/mL
and suspended in 1 mL of PBS. Sulfo-SAED (Thermo Scientific,
Rockford, IL), 2.5 mg and NHS-biotin (Thermo Scientific,
Rockford, IL), 0.5 mg, were dissolved in 50 mL dimethyl sulfoxide
and added to the phage. The reaction proceeded for one hour at
4uC then the phage polyethyleneglycol (PEG) precipitated 3 times
according to standard methods [16] and resuspended in 2 mL
DPBS with 10% FBS. A negative control using M13KE phage
(NEB, Ipswich, MA), which are devoid of display peptides was
utilized. To determine the extent of phage labeling, a standard
curve composed of dilutions of sulfo-SAED in water, starting at
1 mM were made and the fluorescence measured at 350 nm
excitation, 450 nm emission for each concentration. These results
were compared to the fluorescence of the labeled phage at
10
9 PFU/mL and 10
8 PFU/mL.
Pulldown
To determine the phage affinity binding partner, L3.6pl cells
were plated in 10 cm petri dishes and allowed to grow for at least
48 hours to reach 70–90% confluency. Cells were washed twice
with DPBS, then subsequently incubated with the labeled phage
solutions (PDAC selected from NEB PhD 7 M13 library or control
phage M13KE) in the dark for one hour at 4uC. The phage were
removed and the cells again washed 4–66 with DPBS+0.1%
tween, placed on ice, and the sulfo-SAED crosslinker activated by
10 min exposure to UV light using a 30 watt 365 nm lamp
(Spectroline model XX-15A). The cells were then lysed with 1%
Triton X-100 in PBS with mammalian protease inhibitor added
per manufacturer’s instructions (Sigma, St Louis, MO). The cell
lysates were incubated for 20 minutes with 40 mL of Dynal M-280
streptavidin beads (Invitrogen). The beads were washed several
times with 106PBS containing 1% Triton X-100. The beads were
then quickly rinsed with 0.1 M pH 2.2 glycine, then the protein
bound to the phage eluted by cleaving the crosslinker with 50 mL
of the pH 2.2 glycine buffer containing large amounts of
dithiothreitol (DTT). For analysis, half of the solution was run
on a SDS-PAGE gel and stained with either Coomassie blue or a
mass spectroscopy compatible silver stain. Bands excised from the
SDS-PAGE gel were sent for tryptic digest/mass spectroscopy
analysis at either Tufts University core facility or the University of
Virginia mass spectroscopy core facility for identification. The
remaining lysate was utilized for validation experiments (western
blot) once the identity of the protein was determined by mass
spectroscopy.
ELISA
Protein based ELISA. Recombinant purified proteins (R&D
systems (vimentin) and Abcam (pyruvate kinase M2 and Annexin
A2)) were dissolved in PBS and plated onto Nunc Maxisorp plates
(5 mg protein/well) overnight at 4uC. Adsorbed BSA (5%) or
Annexin A2 (for non-Annexin binding clones) were used as a
negative control. Wells were washed, blocked with casein, then
incubated with 50 mL phage (10
9 pfu/mL) for 30 min at 37uC.
After incubation, wells were again washed 66 times with 1%
Tween in PBS, then incubated with anti-M13 antibody-HRP
conjugate (GE healthcare) (1:3000 dilution in PBS) for 1 hr at
37uC. Plates were again washed and developed with TMB then
absorbance read on an absorbance plate reader (Molecular
Devices).
Cell based ELISA. Six wells of a 96 well plate were L3.6pl
cells (20,000 cells/well). Once cells reached 70–80% confluence,
they were washed three times with DPBS+Mg
2+ and Ca
2+ for five
minutes each. Primary antibodies (Abcam ab75933 (Annexin A2)
and Novus Biologicals NBP1-39660 (Pyruvate Kinase M2)) were
diluted to 500 nM in 100 uL DPBS+Mg
2+ and Ca
2+ with 1% BSA
and incubated on ice with the cells in triplicate. For a negative
control, cells were incubated on ice with 100 uL DPBS+Mg
2+ and
Ca
2+ with 1% BSA. The wells were then washed three times with
DPBS+Mg
2+ and Ca
2+ for five minutes each. Secondary
antibodies anti-Rabbit IgG (GE Healthcare NA9340V (Annexin
A2) and anti Goat IgG (R&D Systems HAF109 (Pyruvate Kinase
M2)) were diluted 1:1000 in 100 uL DPBS+Mg
2+ and Ca
2+ with
1% BSA and incubated with all wells for 30 minutes on ice.
Subsequent to incubation, the wells were then washed three times
with DPBS+Mg
2+ and Ca
2+ for five minutes each. 100 uL of TMB
was added to each well and the plate incubated at RT for
15 minutes. Absorbance was then read on an absorbance plate
reader at a wavelength of 650 nm.
Cell fractionation
L3.6pl cells grown to 80–90% confluency in a 10 cm petri dish
were washed several times with PBS, then mixed with 5 mL
hypotonic lysis buffer (10 mM HEPES, pH 7.4, 15 mM KCl,
2 mM MgCl2 and protease inhibitors). The cells were scrapped off
the dish then transferred to an Eppendorf tube where they were
incubated for 2 hours on ice. To remove cellular debris and pellet
nuclei, the cells were then centrifuged at 1300 g for 5 min. The
nuclear fraction was washed twice with PBS then saved for western
blot analysis. The supernatant was centrifuged at 100,000 g for
30 min to separate the cell membrane fraction, which was washed
26with water, from the cytoplasm fraction. Both were saved for
western blot analysis.
Tissue microarrays
Tissue microarrays were prepared and scored by the University
of Virginia Biorepository and Tissue Research Facility. Needle
biopsies of human cancer and normal controls were sectioned onto
glass slides and antibody stained using protocols established by
staining tissue sections known to express the antigen of interest.
The cancers selected were the 20 of the most common lethal
human carcinomas: 12 samples each of colon and rectum
adenocarcinoma, prostate adenocarcinoma, pancreatic adenocar-
cinoma, ovarian papillary carcinoma, endometrioid carcinoma,
and transition cell (urothelial) carcinoma; 11 cases of head and
neck squamous cell carcinoma; 6 cases each of small cell
carcinoma of the lung, lung adenocarcinoma, breast ductal
Identification of Novel Cancer Markers
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duct cholangiocarcinoma, esophageal adeno- and squamous cell
carcinoma, and stomach intestinal and signet ring adenocarcino-
mas; 5 samples each of lung squamous cell carcinoma and clear
cell renal carcinoma; and three samples each of papillary and
chromophobe type renal carcinoma. The stained tissues were
graded by a pathologist for number of cells stained (0–3) and
intensity of staining (0–3), and the two numbers multiplied
together. The stained tissues were graded by a pathologist for
number of cells stained (0, 1=,25%, 2=25–75%, 3=.75%)
and intensity of staining (0, 1=weak, 2=moderate, 3=strong),
and the two numbers multiplied together for an index score.
The tissue used in the immunohistochemical stains were
obtained retrospectively from archival clinical tissue samples by
the UVA Biorepository and Tissue Research Facility (BTRF), with
review and authorization by the UVA IRB (Protocol #13281).
The tissue was used to create a tissue microarray (TMA) with
samples identified by a research code created by the BTRF. The
TMA was provided to the investigators thus de-identified and used
in this study with separate UVA IRB authorization (Protocol #
13310).
Results
As proof of principle, we determined the surface markers of
pancreatic cancer from a previously published selection for phage
that specifically bind pancreatic cancer cells culled from transgenic
animals and also human derived PDAC cell lines [15]. Not all of
the 30 phage clones selected have ideal binding properties; phage
clones with poor specificity are unlikely to yield relevant proteins
and poor affinity will make it difficult to identify a protein binding
partner. To reduce the 30 selected clones to the most promising,
the phage clones were first ranked by specificity (defined as the
ratio of binding to target cell line vs a background cell
line)(Fig. 1A); those with ratios at or below one were removed
from consideration, discarding 33% of the phage clones. To
further refine the rankings, the weighted sum of the specificity and
affinity was used (Fig. 1B). Specificity was weighted more heavily
than affinity because the relevance of the binding partner of clones
of poor specificity is suspect. Phage with a combined weighted
average of less than 1 were discarded.
The methodology for identifying the cell-surface binding
partners of the phage is very similar to an immunoprecipitation.
Phage were labeled with biotin and sulfo-SAED, a photoactive
crosslinker. Loading of sulfo-SAED was characterized by fluores-
cence spectroscopy to be 660 photolinkers/plaque forming unit.
These labeled phage clones were incubated with the cells then
photolysed to activate the sulfo-SAED; crosslinking the phage with
the protein they bind to. The cells were lysed, the phage and
protein extracted with streptavidin beads and the cross linked
protein released by disulfide cleavage, then analyzed by SDS/
PAGE. Gel analysis demonstrated that Clone 8 has one major
band at 60 KDa (Fig. 2A). Tryptic digest of the band followed by
mass spectroscopic analysis identified pyruvate kinase M2 as the
protein present in the analyzed band (Fig. 2B). In contrast Clone
15 yielded a band at 37 KDa (Fig. 2C) that upon analysis was
revealed to be annexin A2 (Fig. 2D). To confirm the mass
spectroscopy data, the samples from the pulldowns were examined
by western blotting (Fig. 3A and 3E). As a further independent
confirmation of the protein binding partner of the phage clones,
ELISA was used to examine the phage binding to recombinant
proteins (Fig. 3B and 3F). For example, phage clone 8 had a 9-fold
higher binding to pyruvate kinase M2 when compared with BSA.
In addition, clone 15 was specific to Annexin A2 as it had 5 fold
higher binding when compared with BSA. A few phage clones
were cross examined against proteins other than BSA that did not
match their binding partner to control against general non-specific
binding to other proteins (Fig. 3B).
Several of these proteins have not been reported on the cell
membrane in pancreatic cancer, and their known functions are
not compatible with location on the cell surface. Therefore, to test
whether the identified proteins are present on the membrane, cells
were fractionated into cytoplasm, membrane, and nuclear
fragments and examined by western blot. In all the clones
examined, the protein was present in the membrane fraction as
demonstrated in Fig. 3C and 3G. An ELISA was performed on
intact, non-permeabilized cells to further determine the presence
and accessibility of the proteins on the cell membrane. L3.6pl cells
were incubated with Annexin A2 antibody, pyruvate kinase M2
antibody or secondary only. Annexin A2 antibody had a 4.2 fold
higher binding to cells when compared with secondary antibody
alone (Fig. 3D). Similarly, pyruvate kinase M2 had a 5.6 fold
higher binding to cells when compared with secondary antibody
alone demonstrating (Fig. 3H) the accessibility of the proteins on
the cell surface.
Ofthe30clonesidentifiedinthe originalscreen,16wereretained
for further analysis after removing clones with inadequate affinity
and specificity, for which we wereable to identify 15 affinity binding
partners (Table 1). Each of these clones except 9 and 14 were
validated by ELISA against recombinant protein to verify the
protein bindingpartner. The exceptionsbind to a specific isoform of
histone H1 that we were unable to obtain as a recombinant protein.
The gels from clones that bound to the same protein all had very
similar appearances; for example, all the annexin A2 binding clones
gavegelsthatlookedlikethatofpanc15(fig.2C).Inalmostallcases,
the strongest band was the protein the phage bound to as validated
by western blot and phage ELISA against purified protein.
While these proteins were verified to be associated with the
surface of the L3.6pl cell line, we sought to determine the potential
relevance to pancreatic cancer of selected proteins through
immunohistochemistry. Antibodies to either pyruvate kinase M2
or plectin were used to determine the expression levels and extent
of staining in a series of human biopsy specimens (Fig. 4). These
were chosen as neither have been previously reported in
pancreatic cancer whereas Annexin A2 is a known protein
expressed in pancreatic cancer. As the kRAS mutation that
initiates pancreatic cancer [17] is common to many other cancers
[18], the immunohistochemistry was conducted in a tissue
microarray format with 20 of the most common lethal human
cancers (n=3–12 patients for each cancer). A pathologist ranked
the stained tissues for percentage of cells stained (0–3) and intensity
of staining (0–3), with the average product of these shown in Fig. 4.
Plectin shows strong membrane staining in pancreatic cancer
(Fig. 4A) and is significant in other cancers including bile duct
cholangiocarcinoma, lung adenocarcinoma, lung squamous cell
carcinoma, ovarian cancer, and intestinal type stomach cancer
(Fig. 4B). Closer examination of a representative pancreatic cancer
sample (Fig. 4A) shows cytoplasmic and membrane staining,
consistent with the cell fractionation data [15]. Pyruvate kinase
M2 also showed strong staining in pancreatic cancer and almost all
other cancer types (Fig. 4D), with both cytoplasmic and membrane
staining (Fig. 4C). These data suggest that both of these may be
potential markers of pancreatic cancer and other cancers as well.
Discussion
Proteomic based strategies that provide for the unbiased
identification of molecules and importantly their post-transcrip-
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information and are an important complement to genomic
strategies. However, the enormity of the proteome and limitations
in proteomic methods make it difficult to determine the targets
that are particularly relevant to human disease. Therefore, we
have developed a functional proteomics method based on phage
display screening and biochemical techniques to fill this void. The
described method is robust, easy to use, and a generally applicable
approach to other diseases, tissues, and potentially other screening
platforms. In this method, the selected phage clones, which are
cheap and easy to produce, are used directly as the probes,
bypassing many of the steps required for other partner
identification strategies. Further, by including the crosslinking
step, harsh detergents and conditions sometimes necessary to
extract transmembrane proteins from the membrane but would
break the protein interaction can be used and thus, these binding
partners can be identified
It is remarkable that the phage particles do not crosslink
randomly to surface proteins (Fig. 2A). The particle is 1 um long,
with hundreds of photoactivatable crosslinkers arrayed randomly
along its entire length. The specific target-binding peptide is at one
tip of that particle, 1 um away from the most distant crosslinkers.
If a target-bound particle were able to lie parallel to the cell
surface, it could potentially be crosslinked to any surface protein
within a 1-um radius of that specific target. Presumably, the
population of proteins within such a large radius is indistinguish-
able from a random sampling of all the cell’s surface molecules.
According to this scenario, therefore, all clones should crosslink to
a random sampling of surface molecules, irrespective of the
binding specificity of their displayed peptides. Our results are
entirely inconsistent with this expectation: different phage clones
crosslink to just one or a few surface proteins, and those proteins
differ from clone to clone. Moreover, the binding specificity of the
displayed peptides has been corroborated in multiple ways that
are completely independent of crosslinking. In light of these
considerations, we favor an alternative scenario, according to
which target-bound particles are constrained to lie perpendicular
to the cell surface, so that only crosslinkers within a few
nanometers of the target-binding peptide are close enough to
crosslink to surface proteins. Within such a narrow radius of
reactivity, it is entirely plausible that the actual target protein
predominates, in full accord with our results. In support of this
scenario is the fact that the surfaces of both the phage particle and
the cell are negatively charged, and thus might well repel each
other except where specific target binding overcomes the
repulsion.
For proof of principle, we have utilized the phage clones
identified from a previously performed phage display screen for
peptides specific to pancreatic cancer. Of the 16 phage clones that
made biological sense ie. had specificity and high affinity for
pancreatic cancer, we were able to identify the binding partner of
15 of the phage clones. The proteins identified consist of known
and interestingly, novel surface markers (Table 1). Vimentin [19–
21] and annexin A2 [22–28], the two proteins with the largest
number of associated phage clones, have been shown in the
literature to be on the cell surface of pancreatic cancer. Vimentin
is an intermediate filament protein; part of the cytoskeleton of the
cell [21], and is a marker of the epithelial-mesenchymal transition
[19,20]. Annexin A2 is found in all compartments of the cell
[23,26,29] and has a vast array of functions and binding partners.
Figure 2. Pulldown and mass spectroscopic analysis. Elution sample from Panc 8 (A) and Panc 15 (C) were run on SDS/PAGE then stained with
coomassie. Sequence of pyruvate kinase M2 (B) and Annexin A2 (D), with peptides recovered from tryptic digest of the band from (A) and (C) in red.
doi:10.1371/journal.pone.0022471.g002
Figure 1. Ranking of clones for selection. A) Specificity of each clone as measured by ELISA. Clones in white were insufficiently specific (.1) and
therefore, not used. B) Weighted sum of the specificity and affinity of each clone. Clones in white were not investigated further.
doi:10.1371/journal.pone.0022471.g001
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[23,26–28,30,31]. It binds with gastrin [32], tissue plasminogen
activator [27,28], actin [33], and tenacin C [23] and has been
investigated as a serum [34] and urine [35] biomarker of
pancreatic cancer. Expression levels of annexin A2 are related to
resistance to gemcitabine [36], which is mediated by the
interaction of an alternatively spliced segment of tenascin-C with
annexin A2 under the control of the PI3K/Akt and NF-kB
pathways [37]. While these effects are shown from whole cell
lysates of annexin A2, if the same relationship of high expression
correlating with gemcitabine resistance holds on the cell surface,
we have identified 6 peptides that can be used to probe this
phenomenon.
Pyruvate kinase M2 isoform is an embryonicly expressed
enzyme not normally found in healthy individuals. However, it
is the sole isoform expressed in most forms of cancer [38], even
though it is less efficient than other isoforms. It has been
investigated as a serum tumor marker [39–41], but only two
contradictory reports mention surface expression [42,43] in
pancreatic cancer with one demonstrating surface expression
[43] and the other absence of surface expression [42]. However,
the paper reporting absent surface expression also claims to find
the protein expressed in the normal pancreas and in chronic
pancreatitis [42]. Our work demonstrated strong expression in 19
of 20 cancers examined including pancreatic cancer with only
hepatocellular carcinoma devoid of any staining.
Figure 3. Validation of affinity partner for phage clones. A) Western blot of the protein that binds to clone 8, probed using anti-pyruvate
kinase M2 antibody. B) ELISA of clone 8 incubated with purified pyruvate kinase M2, or with BSA or recombinant annexin A2 as negative controls. C)
Western blot of cell fractionation using anti-pyruvate kinase M2 antibody D) ELISA on intact, non-permeabilized L3.6pl cells with anti-pyruvate kinase
M2 antibody. E) Western blot of clone 15 associated protein probed with anti annexin A2 antibody. E) ELISA showing binding of clone 15 to annexin
A2 protein. F) Western blot of cell fractionation using anti annexin A2 antibody. G) ELISA on intact, non-permeabilized L3.6pl cells with anti-Annexin
A2 antibody.
doi:10.1371/journal.pone.0022471.g003
Table 1. Listing of the phage clones, their binding peptide
sequence, and their associated targeted protein.
Clone Sequence Affinity ligand
Panc 3 VSQTLRL Annexin A2
Panc 4 GSLYPTA Annexin A2
Panc 15 TMAPSIK Annexin A2
Panc 19 QTLPKLY Annexin A2
Panc 20 RLAPIN Annexin A2
Panc 22 VNDRNVK Annexin A2
Panc 5 QSPDEVW Vimentin
Panc 7 WMHQPTY Vimentin
Panc 16 AKSSLNS Vimentin
Panc 17 TQHQVTA Vimentin
Panc 18 APWTHNS Vimentin
Panc 8 TGTAYPY Pyruvate kinase M2
Panc 9 LKPTHHA Histone H1
Panc 14 YATHHNT Histone H1
Panc 27 KTLLPTP Plectin 1
doi:10.1371/journal.pone.0022471.t001
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cell surface, an unexpected finding given the function of histones
and the observation that histones present in cell culture media will
cross the cell membrane and travel to the nucleus [44–47]. The
function of histone HI is to sequester the ends of DNA into the
nucleosome and link nucleosomes together. Further literature
searching however, shows that histone H1 was reported on the
surface of two melanoma cell lines [9] and on neurons [48] and
Schwann cells [48]. Apoptotic cells [49–51] and many cells of the
immune system [52–57] express nucleosomes, including histone
H1, on the cell surface, which bind to various compounds such as
sulfonated polysacharaides [56,57], plasminogen [53,58] and
thyroglobulin [52], and act as antimicrobial agents [59]. To our
knowledge, this is the first report of the presence of histone H1 on
the surface of pancreatic cancer. Its role and function in pancreatic
tumorigenesis and or metastasis is currently unknown. However,
due to the immune system expression, histone H1 maymake a
poor target for either imaging or drug delivery.
Another interesting novel pancreatic cancer specific protein,
plectin, was identified through our method. In normal epithelial
cells, predominately skin and muscle cells, plectin is a major
component of the hemidesmosome- linking the cell to its basement
membrane. Patients that have mutations in plectin have a severe
skin blistering disease, epidermolysis bullosa, underscoring the
importance of plectin to the hemidesmosome and cell-cell
junctions. When plectin is expressed in cells, it is found in the
cytoplasm. However, in pancreatic cancer, it is expressed both in
the cytoplasm and on the cell surface. Recently, plectin was shown
to be expressed in all pancreatic cancers examined [15,60], but has
no expression in the healthy pancreas or in other benign
conditions. Experiments are underway to determine the mecha-
nism of the cell surface population of plectin and its potential role
in pancreatic cancer.
Of the 16 phage clones examined, it proved possible to
determine the binding partner of 15, a success rate of ,94%. We
were unable to find the affinity partner of the 16
th clone, clone 1,
despite its good specificity and affinity, even after several attempts.
There are two possible reasons for this. The original screen was
conducted on cells derived from a mouse model of pancreatic
cancer [15], as this allowed access to needed normal pancreatic
ductal cells that otherwise would be very difficult to obtain. The
affinity binding partners were determined on a human cancer cell
Figure 4. Tissue microarray data. Values are pathologist’s scoring of number of cells stained (0–3) and intensity of staining (0–3) multiplied
together. A) Representative tumor section stained for plectin. Note the membrane staining. B) Pathologist’s scoring of human cancer biopsy
specimens stained for plectin. C) Representative PDAC tumor biopsy section stained for pyruvate kinase M2. D) Pathologist’s scoring of pyruvate
kinase M2 stained human cancer biopsy tissue sections.
doi:10.1371/journal.pone.0022471.g004
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possible that clone 1 binds solely to a mouse protein and does not
cross-react with the human variant. Alternatively, the protein that
clone 1 binds to is an artifact of the cell line the screen was
conducted on and is not general to pancreatic cancer in humans.
Here we report a new method of cell surface proteomic analysis
using phage to probe the cell surface followed by identification of
the protein the various phage clones bind to. The method gives a
snapshot of the most abundant proteins on the membrane that are
overexpressed due to disease and have identified several proteins,
which upon further study, may give important insights into
pancreatic cancer. Further, the original phage display screen
identified peptides that can then be converted into imaging agents
that may aid in diagnosis and targeted drug delivery for pancreatic
cancer.
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